1 Antonetti, D. A., Klein, R. & Gardner, T. W. Diabetic retinopathy. N Engl J Med 366, 1227-1239, doi:10.1056/NEJMra1005073 (2012).
2 Ghirlanda, G., Di Leo, M. A., Caputo, S., Cercone, S. & Greco, A. V. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab Rev 13, 15-35, doi:10.1002/(sici)1099-0895(199703)13:1<15::aid-dmr176>3.0.co;2-m (1997).
3 Barber, A. J. & Baccouche, B. Neurodegeneration in diabetic retinopathy: Potential for novel therapies. Vision Res 139, 82-92, doi:10.1016/j.visres.2017.06.014 (2017).
4 Du, Y., Veenstra, A., Palczewski, K. & Kern, T. S. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci U S A 110, 16586-16591, doi:10.1073/pnas.1314575110 (2013).
5 Miller, W. P. et al. Deletion of the Akt/mTORC1 Repressor REDD1 Prevents Visual Dysfunction in a Rodent Model of Type 1 Diabetes. Diabetes 67, 110-119, doi:10.2337/db17-0728 (2018).
6 Huang, H. et al. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci 52, 1336-1344, doi:10.1167/iovs.10-5768 (2011).
7 Huang, H. et al. Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition. Diabetes 64, 200-212, doi:10.2337/db14-0016 (2015).
8 Hu, J. et al. Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy. Nature 552, 248-252, doi:10.1038/nature25013 (2017).
9 Duh, E. J., Sun, J. K. & Stitt, A. W. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI Insight 2, doi:10.1172/jci.insight.93751 (2017).
10 Nguyen, Q. D. et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol 96, e1-e9, doi:10.1111/aos.13325 (2018).
11 Van Bergen, T. et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res 69, 116-136, doi:10.1016/j.preteyeres.2018.10.006 (2019).
12 Diabetic Retinopathy Clinical Research, N. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372, 1193-1203, doi:10.1056/NEJMoa1414264 (2015).
13 Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7, 575-583, doi:10.1038/87904 (2001).
14 Incio, J. et al. PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res 22, 2993-3004, doi:10.1158/1078-0432.CCR-15-1839 (2016).
15 Albonici, L., Giganti, M. G., Modesti, A., Manzari, V. & Bei, R. Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. Int J Mol Sci 20, doi:10.3390/ijms20122970 (2019).
16 Jiao, W. et al. Distinct downstream signaling and the roles of VEGF and PlGF in high glucose-mediated injuries of human retinal endothelial cells in culture. Sci Rep 9, 15339, doi:10.1038/s41598-019-51603-0 (2019).
17 Lazzara, F. et al. Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway. Biochem Pharmacol 168, 341-351, doi:10.1016/j.bcp.2019.07.021 (2019).
18 Huang, H. et al. Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems. FASEB J 33, 13695-13709, doi:10.1096/fj.201901353R (2019).
19 Valenzuela, D. M. et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 96, 1904-1909, doi:10.1073/pnas.96.5.1904 (1999).
20 Nguyen, Q. D. et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitreous 6, 48, doi:10.1186/s40942-020-00250-z (2020).
21 Whitehead, M., Osborne, A., Widdowson, P. S., Yu-Wai-Man, P. & Martin, K. R. Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential. J Diabetes Res 2019, 5140521, doi:10.1155/2019/5140521 (2019).
22 Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180, doi:10.1016/s0092-8674(00)81813-9 (1996).
23 Jeansson, M. et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 121, 2278-2289, doi:10.1172/JCI46322 (2011).
24 Yuan, H. T., Khankin, E. V., Karumanchi, S. A. & Parikh, S. M. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 29, 2011-2022, doi:10.1128/MCB.01472-08 (2009).
25 Teichert, M. et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun 8, 16106, doi:10.1038/ncomms16106 (2017).
26 Patel, J. I., Hykin, P. G., Gregor, Z. J., Boulton, M. & Cree, I. A. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol 89, 480-483, doi:10.1136/bjo.2004.049940 (2005).
27 Lip, P. L. et al. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 88, 1543-1546, doi:10.1136/bjo.2004.048587 (2004).
28 Hammes, H. P. et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53, 1104-1110, doi:10.2337/diabetes.53.4.1104 (2004).
29 Rangasamy, S., Srinivasan, R., Maestas, J., McGuire, P. G. & Das, A. A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 52, 3784-3791, doi:10.1167/iovs.10-6386 (2011).
30 Khalaf, N. et al. Role of Angiopoietins and Tie-2 in Diabetic Retinopathy. Electron Physician 9, 5031-5035, doi:10.19082/5031 (2017).
31 Wimmer, R. A. et al. Human blood vessel organoids as a model of diabetic vasculopathy. Nature 565, 505-510, doi:10.1038/s41586-018-0858-8 (2019).
32 Lennikov, A. et al. Synergistic interactions of PlGF and VEGF contribute to blood-retinal barrier breakdown through canonical NFkappaB activation. Exp Cell Res 397, 112347, doi:10.1016/j.yexcr.2020.112347 (2020).
33 Huang, H., Parlier, R., Shen, J. K., Lutty, G. A. & Vinores, S. A. VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One 8, e71808, doi:10.1371/journal.pone.0071808 (2013).
34 Huang, H., Shen, J. & Vinores, S. A. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One 6, e21411, doi:10.1371/journal.pone.0021411 (2011).
35 Wimmer, R. A., Leopoldi, A., Aichinger, M., Kerjaschki, D. & Penninger, J. M. Generation of blood vessel organoids from human pluripotent stem cells. Nat Protoc 14, 3082-3100, doi:10.1038/s41596-019-0213-z (2019).
36 Giaever, I. & Keese, C. R. Micromotion of mammalian cells measured electrically. Proceedings of the National Academy of Sciences of the United States of America 88, 7896-7900 (1991).
37 Huang, H. et al. Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. Investigative ophthalmology & visual science 52, 7565-7573, doi:10.1167/iovs.11-8002 (2011).
38 Saddala, M. S. et al. Discovery of novel L-type voltage-gated calcium channel blockers and application for the prevention of inflammation and angiogenesis. J Neuroinflammation 17, 132, doi:10.1186/s12974-020-01801-9 (2020).
39 Saddala, M. S., Lennikov, A., Mukwaya, A. & Huang, H. Transcriptome-Wide Analysis of CXCR5 Deficient Retinal Pigment Epithelial (RPE) Cells Reveals Molecular Signatures of RPE Homeostasis. Biomedicines 8, doi:10.3390/biomedicines8060147 (2020).
40 Verbeke, G. & Molenberghs, G. Linear Mixed Models for Longitudinal Data. (New York: Springer-Verlag, Inc, 2000).
41 Sweeney, M. & Foldes, G. It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease. Front Cardiovasc Med 5, 154, doi:10.3389/fcvm.2018.00154 (2018).
42 Huang, H. Pericyte-Endothelial Interactions in the Retinal Microvasculature. Int J Mol Sci 21, doi:10.3390/ijms21197413 (2020).
43 Piera-Velazquez, S. & Jimenez, S. A. Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases. Physiol Rev 99, 1281-1324, doi:10.1152/physrev.00021.2018 (2019).
44 Bischoff, J. Endothelial-to-Mesenchymal Transition. Circ Res 124, 1163-1165, doi:10.1161/CIRCRESAHA.119.314813 (2019).
45 Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y. & Johnson, K. R. Cadherin switching. J Cell Sci 121, 727-735, doi:10.1242/jcs.000455 (2008).
46 Lennikov, A., Mukwaya, A., Saddala, M. S. & Huang, H. Deficiency of C-X-C chemokine receptor type 5 (CXCR5) gene causes dysfunction of retinal pigment epithelium cells. Lab Invest 101, 228-244, doi:10.1038/s41374-020-00491-4 (2021).
47 Caporali, A. et al. Contribution of pericyte paracrine regulation of the endothelium to angiogenesis. Pharmacol Ther 171, 56-64, doi:10.1016/j.pharmthera.2016.10.001 (2017).
48 Gavard, J. & Gutkind, J. S. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8, 1223-1234, doi:10.1038/ncb1486 (2006).
49 Gavard, J., Patel, V. & Gutkind, J. S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14, 25-36, doi:10.1016/j.devcel.2007.10.019 (2008).
50 Cai, J., Kehoe, O., Smith, G. M., Hykin, P. & Boulton, M. E. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 49, 2163-2171, doi:10.1167/iovs.07-1206 (2008).
51 Milam, K. E. & Parikh, S. M. The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation. Tissue Barriers 3, e957508, doi:10.4161/21688362.2014.957508 (2015).
52 Duran, E. K. et al. Plasma Placental Growth Factor Concentrations Are Elevated Well in Advance of Type 2 Diabetes Mellitus Onset: Prospective Data From the WHS. J Am Heart Assoc 8, e012790, doi:10.1161/JAHA.119.012790 (2019).
53 Al Kahtani, E. et al. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye (Lond) 31, 529-536, doi:10.1038/eye.2016.246 (2017).
54 Mesquita;, J. et al. Comparison of serum and vitreous PIGF in diabetic retinopathy patients and non-diabetic patients. IOVS 56, ARVO abstract 5179 (2015).
55 Suzuma, K. et al. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem 275, 40725-40731, doi:10.1074/jbc.M006509200 (2000).
56 Wu, J. H. et al. Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med 12, e10154, doi:10.15252/emmm.201810154 (2020).
57 Liu, D. et al. Erythropoietin maintains VE-cadherin expression and barrier function in experimental diabetic retinopathy via inhibiting VEGF/VEGFR2/Src signaling pathway. Life Sci 259, 118273, doi:10.1016/j.lfs.2020.118273 (2020).